Trinity Biotech (ADR)
Makes rapid HIV tests, haemoglobin systems and specialty clinical diagnostics.
Something off on this page? Send us feedback.
Profile
Sells diagnostic instruments, recurring reagents and test kits, and laboratory services centered on rapid HIV testing, haemoglobin systems and specialty assays. Develops wearable biosensors and biomarker tests while distributing directly in selected markets and through partners elsewhere.
Builds and sells rapid HIV point-of-care tests, haemoglobin and HbA1c analyzers, infectious-disease and autoimmune assays, and laboratory testing services. The Immco reference laboratory serves U.S. laboratories and hospitals; sales use direct channels in selected markets and distributors, strategic partners, and nongovernmental bodies elsewhere.
Develops the CGM+ wearable biosensor, PrePsia preeclampsia-risk test, and EpiCapture urine-based test for aggressive prostate-cancer risk. Trinovium is developing direct-to-chip liquid-cooling fluids and a connected monitoring platform, but it was at technical-validation, partner-engagement, and customer-qualification stages at launch.
Existing medical products and the Immco laboratory remain subject to applicable FDA, European, UK, Canadian, CLIA, and New York laboratory requirements. Rapid-HIV demand partly depends on foreign-aid procurement, while outsourced offshore production transitions created timing variability.
Company facts
Key statistics
Year to date −56.9% · Average volume (30d) 33.1K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | −$0.31 | −$0.23 | +25.8% | $10.7M | — | — | +1.75% |
| Apr 30, 2026 | −$0.32 | −$0.90 | −181.3% | $15.0M | $11.1M | −26.2% | +1.28% |
| Jan 2, 2026Q3 FY25 | −$11.10 | −$28.20 | −154.1% | $14.5M | $11.1M | −23.7% | +2.32% |
| Dec 26, 2025Q3 FY25 | −$44.40 | −$8.22 | +81.5% | $10.5M | $14.2M | +35.7% | −17.90% |
Financial highlights
| 12 quarters | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | |
|---|---|---|---|---|---|---|---|
| Revenue | $15.2M | $15.9M | $7.6M | $11.0M | $14.2M | $11.1M | |
| Gross profit | $5.3M | $4.9M | $1.6M | $4.3M | $6.1M | $3.5M | |
| Operating income | −$2.6M | −$11.5M | −$4.7M | −$3.0M | −$536.6K | −$2.9M | |
| Net income | −$4.8M | −$17.0M | −$8.8M | −$6.0M | −$5.1M | −$17.5M | |
| Diluted EPS | −$13.80 | −$35.88 | −$14.46 | −$9.72 | −$8.22 | −$28.20 | |
| Gross margin | 35.0% | 30.8% | 20.7% | 39.5% | 42.7% | 32.1% | |
| Operating margin | -16.9% | -72.6% | -62.5% | -27.7% | -3.8% | -26.6% |
Fiscal years (4-quarter sums)FY21 $93.0M · FY22 $74.8M · FY23 $56.8M · FY24 $61.6M · FY25 $43.9M
Revenue by product · FY25
Revenue by geography · FY25
Balance sheet, Dec 31, 2025Cash & short-term investments $5.1M · Total debt $138.0M · Total assets $105.2M · Shareholders' equity −$72.0M
Dividends
No dividends on record.
Ownership
Shares outstanding — · Float —
Shares outstanding and float — provider count disagrees with the price.
Insiders — filings are in the shares behind the receipt.
The provider's share count does not square with the market price, so neither it nor anything divided by it is shown.
This listing is a depositary receipt and the Form 4 positions here are filed in the shares behind it, a different unit from the share count and in a ratio the filings never state, so no insider percentage is shown.
The institutional figure is the one the filers report, not a quotient recomputed on the share count.
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- Abbott
Rapid HIV, HbA1c, and CGM overlap across key testing workflows.
- Bio-Rad Laboratories
Core rival in HbA1c, haemoglobin-variant, and autoimmunity workflows.
- Dexcom
Commercial CGM benchmark for the developing multi-sensor wearable.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Trinity Biotech (ADR) | $9.60 | −0.41% | $196.0M | — | — | 4.5 | −30.2% |
| Abbott | $112.20 | −0.22% | $194.62B | 36.2 | 19.4 | 4.2 | +13.0% |
| Bio-Rad Laboratories | $387.70 | +0.02% | $10.44B | 47.0 | 37.6 | 4.0 | −0.1% |
| Dexcom | $90.77 | −0.06% | $34.27B | 35.9 | 32.4 | 6.9 | +13.1% |
| Median | 36.2 | 32.4 | 4.2 | +13.0% |